Novel Developments in Stem Cell Mobilization

Focus on CXCR4

Nonfiction, Health & Well Being, Medical, Specialties, Oncology, Medical Science, Pharmacology
Cover of the book Novel Developments in Stem Cell Mobilization by , Springer New York
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9781461419600
Publisher: Springer New York Publication: February 15, 2012
Imprint: Springer Language: English
Author:
ISBN: 9781461419600
Publisher: Springer New York
Publication: February 15, 2012
Imprint: Springer
Language: English

Recently the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology research guides the way to the rational development effective antagonists. One antagonist, plerixafor, is clinically approved now for stem cell mobilization of lymphoma and myeloma patients. This allows patients to receive potentially life-saving treatment which could not have been administered otherwise. Through early clinical studies it was recognized that CXCR4 antagonists also mobilize malignant hematopoetic cells, i.e. leukemia cells. In preclinical studies a sensitization of mobilized leukemic cells to standard cytotoxic chemotherapy could be shown. Clinical studies are under way. CXCR4 antagonists are an exciting new class of compounds which are also employed for the mobilization of angiogenic cells or for the treatment of solid tumors. In this book a concise review of the current status of knowledge and future developments will be presented.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Recently the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology research guides the way to the rational development effective antagonists. One antagonist, plerixafor, is clinically approved now for stem cell mobilization of lymphoma and myeloma patients. This allows patients to receive potentially life-saving treatment which could not have been administered otherwise. Through early clinical studies it was recognized that CXCR4 antagonists also mobilize malignant hematopoetic cells, i.e. leukemia cells. In preclinical studies a sensitization of mobilized leukemic cells to standard cytotoxic chemotherapy could be shown. Clinical studies are under way. CXCR4 antagonists are an exciting new class of compounds which are also employed for the mobilization of angiogenic cells or for the treatment of solid tumors. In this book a concise review of the current status of knowledge and future developments will be presented.

More books from Springer New York

Cover of the book Microsurgery for Cerebral Ischemia by
Cover of the book Operative Treatment of Elbow Injuries by
Cover of the book Web-Scale Data Management for the Cloud by
Cover of the book Cancer and the Heart by
Cover of the book Database of Piano Chords by
Cover of the book Photonic Network-on-Chip Design by
Cover of the book Male Reproductive Cancers by
Cover of the book Life-Cycle Assessment of Semiconductors by
Cover of the book The Painted Stork by
Cover of the book Metagenomics of the Human Body by
Cover of the book Emerging Technologies for Information Systems, Computing, and Management by
Cover of the book Environmental Analysis by Electrochemical Sensors and Biosensors by
Cover of the book Argillaceous Rock Atlas by
Cover of the book Targeted Cancer Treatment in Silico by
Cover of the book Therapy Dogs in Cancer Care by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy